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BRIEF DEFINITIVE REPORT
        Membranous or microfold cells (M cells), which 
are located in the follicle-associated epithelium 
(FAE) of Peyer  ’  s patches (PPs) or nasopharynx-
associated lymphoid tissue (NALT), play a pivotal 
role in the uptake of luminal antigens for induc-
tion of antigen-specifi  c immune responses in both 
systemic and mucosal compartments (  1  ). Unlike 
their neighboring columnar epithelial cells, M 
cells are morphologically unique because they 
have irregular and short microvilli for the eff  ec-
tive uptake of ingested or inhaled antigens from 
luminal sites in the aerodigestive tract; they sub-
sequently transport the sampled antigen to pro-
fessional antigen-presenting cells (e.g., dendritic 
cells) to initiate antigen sensitization (  2  ). 
  The mucosal immune system consists of two 
types of immunologically important sites, termed 
  “  inductive  ”   and   “  eff  ector  ”   tissues, connected 
by the common mucosal immune system (  3  ). 
In general, antigen sensitization occurs at induc-
tive sites, such as PPs, after antigen uptake by 
M cells. Induction of antigen-specifi  c T helper 2 
(Th2) cell  –  mediated IgA responses and Th1 cell  –   
and CTL-dependent immune responses then oc-
curs at eff  ector sites such as the lamina propria (  3  ). 
However, our recent study demonstrated that 
the eff  ector sites are also able to take up antigen, 
because antigen-sampling cells termed villous 
M cells are distributed in the intestinal villous 
epithelium (  4  ), and antigen-specifi  c mucosal im-
mune responses can be induced in PP-defi  cient 
mice (  5  ). 
  Although mucosal vaccination is thought 
to be an ideal strategy for combating mucosal 
infectious diseases, only a few mucosal vaccines 
(e.g., polio vaccine and infl  uenza vaccine) are 
CORRESPONDENCE  
 Hiroshi  Kiyono: 
 kiyono@ims.u-tokyo.ac.jp
      The online version of this article contains supplemental material.   
  A novel M cell  –  specifi  c carbohydrate-
targeted mucosal vaccine eff  ectively induces 
antigen-specifi  c immune responses 
  Tomonori Nochi,  1,3   Yoshikazu Yuki,  1,3   Akiko Matsumura,  1,3   Mio Mejima,  1,3   
Kazutaka Terahara,  1,3   Dong-Young Kim,  1,3   Satoshi Fukuyama,  1,3   
Kiyoko Iwatsuki-Horimoto,  2,3   Yoshihiro Kawaoka,  2,3   Tomoko Kohda,  4   
Shunji Kozaki,  4   Osamu Igarashi,  1,3   and Hiroshi Kiyono  1,3   
  1  Division of Mucosal Immunology,   2  Division of Virology, The Institute of Medical Science, The University of Tokyo, 
Tokyo 108-8639, Japan 
  3  Core Research for Evolutional Science and Technology, Japan Science and Technology Corporation, Saitama 332-0012, Japan 
  4  Laboratory of Veterinary Epidemiology, Department of Veterinary Science, Graduate School of Life and Environmental 
Sciences, Osaka Prefecture University, Osaka 599-8531, Japan   
  Mucosally ingested and inhaled antigens are taken up by membranous or microfold cells 
(M cells) in the follicle-associated epithelium of Peyer  ’  s patches or nasopharynx-associated 
lymphoid tissue. We established a novel M cell  –  specifi  c monoclonal antibody (mAb NKM 
16  –  2-4) as a carrier for M cell  –  targeted mucosal vaccine. mAb NKM 16  –  2-4 also reacted 
with the recently discovered villous M cells, but not with epithelial cells or goblet cells. Oral 
administration of tetanus toxoid (TT)  –   or botulinum toxoid (BT)  –  conjugated NKM 16  –  2-4, 
together with the mucosal adjuvant cholera toxin, induced high-level, antigen-specifi  c 
serum immunoglobulin (Ig) G and mucosal IgA responses. In addition, an oral vaccine for-
mulation of BT-conjugated NKM 16  –  2-4 induced protective immunity against lethal 
challenge with botulinum toxin. An epitope analysis of NKM 16  –  2-4 revealed specifi  city to 
an     (1,2)-fucose  –  containing carbohydrate moiety, and reactivity was enhanced under sialic 
acid  –  lacking conditions. This suggests that NKM 16  –  2-4 distinguishes     (1,2)-fucosylated 
M cells from goblet cells containing abundant sialic acids neighboring the     (1,2) fucose 
moiety and from non-    (1,2)-fucosylated epithelial cells. The use of NKM 16  –  2-4 to target 
vaccine antigens to the M cell  –  specifi  c carbohydrate moiety is a new strategy for develop-
ing highly effective mucosal vaccines. 2790 A NOVEL M CELL–SPECIFIC CARBOHYDRATE-TARGETED MUCOSAL VACCINE | Nochi et al.
but not of UEA-1  –  negative epithelial cells. In addition, an 
electronmicroscopic analysis revealed that NKM 16  –  2-4 spe-
cifi  cally reacted with typical M cells, which have short and 
irregular microvilli and a pocket structure containing lym-
phocytes and/or monocytes (  Fig. 1 B  ). Furthermore, whole-
mount staining analysis revealed that NKM 16 –  2-4 specifi  cally 
reacted with villous M cells, in a manner similar to the reaction 
with PP-associated M cells (  Fig. 1 C  ). 
  M cells recognized by UEA-1 in mice are also present 
in the FAE of NALT, as they are in PPs, and act as antigen-
sampling cells for the induction of mucosal immunity (  15  ), 
although our previous fi  nding demonstrated that the mechanism 
of NALT organogenesis is distinct from that of PP organogene-
sis (  16, 17  ). Recently, it was reported that group A strepto-
coccus infects its hosts through M cells (  15  ), meaning that M 
cells could be defi  ned as a portal cell subset of mucosal infection 
in both the gastrointestinal and respiratory tracts. A subse-
quent immunohistochemical analysis of NALT tissue sections 
revealed that NKM 16  –  2-4 specifi  cally reacted with UEA-1  –
  positive M cells, but not UEA-1  –  positive, morphologically typ-
ical goblet cells with secretory granules (Fig. S2, available at 
http://www.jem.org/cgi/content/full/jem.20070607/DC1). 
These results further suggest the possibility of formulating an 
M cell  –  targeted nasal vaccine with NKM 16  –  2-4 for protection 
against infectious diseases entering through the respiratory 
tract. Thus, in summary, the novel mAb NKM 16  –  2-4 specifi  -
cally reacted with all subsets of M cells, but not epithelial cells 
or goblet cells, located in PPs, NALT, and the intestinal villi; 
i.e., in both the gastrointestinal and respiratory tracts (  Table I  ).   
  Use of NKM 16  –  2-4 to develop an M cell  –  targeted 
mucosal vaccine 
  Because it had been reported that the use of monoclonal anti-
bodies to target injectable vaccine antigen to dendritic cells 
expressing endocytic receptor eff  ectively initiated antigen-
specifi  c immunity (  18, 19  ), we next addressed the characteristics 
of NKM 16  –  2-4 as a carrier vehicle of M cell  –  targeted mu-
cosal vaccines. When we injected FITC-conjugated NKM 
16  –  2-4 or FITC-conjugated control rat IgG into intestinal 
loops containing PPs, FITC-conjugated NKM 16  –  2-4 spe-
cifi  cally attached to the apical surfaces of M cells in the dome 
regions of PPs within 10 min of inoculation, whereas FITC-
conjugated control rat IgG did not (  Fig. 2 A  ).   Furthermore, 
FITC-conjugated NKM 16  –  2-4 was taken into the cytoplas-
mic regions of M cells within 30 min (  Fig. 2 A  ) and reached 
the basal membrane of the M cells within 4 h, indicating that 
NKM 16  –  2-4 could likely be used as a carrier vehicle of orally 
administered vaccine antigen to M cells. 
  To directly confi  rm that M cell  –  targeted mucosal vacci-
nation with NKM 16  –  2-4 is an eff  ective strategy for induc-
ing high-level, antigen-specifi  c immune responses, tetanus 
toxoid (TT) was selected as a prototypical vaccine antigen, as 
TT has been extensively used in our previous experiments to 
elucidate the mechanism of the antigen-specifi  c immune re-
sponses induced in both the mucosal and systemic compart-
ments by mucosal immunization (  20  ). A chimeric complex of 
currently used in humans because they have lower effi   cacy 
than the currently used injectable vaccines in inducing antigen-
specifi  c immune responses (  6  ). Because M cells possess the 
ability to take up luminal antigens, it is logical and attractive 
to develop a system of delivery of vaccine antigen to both 
PP-associated and villous M cells to create an eff  ective muco-
sal vaccine (  7  ). In fact,   Ulex europaeus   agglutinin-1 (UEA-1)  – 
conjugated (  8, 9  ) or     1 protein  –  conjugated nasal vaccination 
(  10, 11  ) induce not only strong antigen-specifi  c plasma IgG 
and mucosal IgA responses but also CTL immunity, because 
UEA-1 specifi  c for     (1,2) fucose specifi  cally reacts with murine 
PP  –  associated and villous M cells (  4, 12  ), and     1 protein de-
rived from reovirus specifi  cally binds to a carbohydrate struc-
ture containing     (2,3)-linked sialic acid on the membranes of 
M cells (  13  ). However, because UEA-1 also reacts strongly 
with goblet cells and the mucus layer covering the intestinal 
epithelium (  14  ), there have been no eff  ective oral vaccines with 
UEA-1 as an M cell  –  targeting vehicle. To overcome this ob-
stacle, we established an M cell  –  specifi  c mAb and developed 
a novel strategy for oral vaccination with high effi   cacy. 
    RESULTS AND DISCUSSION   
  Establishment of an M cell  –  specifi  c monoclonal antibody 
(NKM 16  –  2-4) 
  To characterize the antigen-sampling M cells for development 
of an eff  ective M cell  –  targeted mucosal vaccine, Sprague-
Dawley (SD) rats were immunized 4 times at 2-wk intervals 
with highly purifi  ed (  >  95%) UEA-1  –  positive cells isolated 
from murine PPs to establish an M cell  –  specifi  c mAb. A total of 
1,000 hybridomas were generated and screened by immuno-
histochemical analysis of intestinal tissue sections contain-
ing PPs. On the basis of the initial screening, one clone 
(NKM 16  –  2-4; rat IgG2c), which possessed specifi  city to 
M cells located in the FAE of PPs (  Fig. 1 A  ), was selected.   Half 
of the hybridomas showed no specifi  city to tissue sections; 
    40% of them showed strong reactivity to goblet cells and 
their secretions; and 10% showed reactivity to the microvilli 
in all parts of the intestinal epithelium, including M cells 
and neighboring columnar epithelial cells (unpublished data). 
These initial screening data indicated that the goblet cells 
contained in the immunized UEA-1  –  positive fraction, and 
their secretions, were vastly immunodominant compared 
with M cells. However, importantly, NKM 16  –  2-4 possessed 
no reactivity to UEA-1  –  positive goblet cells located in the 
intestinal villi (  Fig. 1 A  ), indicating that NKM 16  –  2-4 is a novel 
mAb possessing high specifi  city to murine M cells. This is 
unlike the already known murine M cell  –  specifi  c lectin UEA-1, 
which also reacts with goblet cells and their secretions (  14  ). 
In addition, NKM 16  –  2-4 reacted very strongly with the apical 
surfaces of the M cells (  Fig. 1 A  ), rather than the cytoplasm, 
suggesting that it might be able to be used as a carrier vehicle 
of M cell  –  targeted mucosal vaccine. In support of these results, 
fl  ow cytometric and immuno- and lectin-cytochemical analyses 
demonstrated that NKM 16  –  2-4 specifi  cally reacted with the 
surfaces of isolated UEA-1  –  positive M cells (Fig. S1, available at 
http://www.jem.org/cgi/content/full/jem.20070607/DC1), JEM VOL. 204, November 26, 2007  2791
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IgG or 50     g noncoupled TT induced, at best, very low TT-
specifi  c immune responses (  Fig. 2 B  ). In addition, the level of 
the TT-specifi  c immune response induced by TT-conjugated 
UEA-1 was lower than that induced by TT-conjugated NKM 
16  –  2-4. These data suggest that an M cell  –  targeted mucosal 
vaccine with UEA-1 might be insuffi   cient for antigen deliv-
ery to M cells, because the UEA-1  –  based vaccine is trapped by 
goblet cells and their secreting mucus, as well as by M cells. 
Furthermore, 10 times more noncoupled TT (500     g) induced 
a small TT-specifi  c immune response compared with TT-
conjugated NKM 16  –  2-4 containing 50     g TT (  Fig. 2 B  ), per-
haps because of the low effi   cacy of antigen delivery to M cells for 
the induction of antigen-specifi  c immune responses. Although 
the levels of the antigen-specifi  c antibody responses induced 
here by immunization with noncoupled TT and CT tended to 
TT conjugated with NKM 16  –  2-4 or control rat IgG (in total, 
each 200     g contained 50     g TT per mouse) was prepared 
by using avidin  –  biotin complexes (see Materials and methods). 
The prepared complexes consisted of TT and NKM 16  –  2-4 
or control rat IgG; these complexes, or noncoupled TT, were 
orally administered to mice, together with the mucosal adju-
vant cholera toxin (CT). In addition, it has been reported that 
M cell  –  targeted mucosal vaccine with UEA-1 is eff  ective in 
inducing antigen-specifi  c humoral and cellular immunity when 
administered via the nasal route (  8, 9  ); therefore, we prepared 
an orally administered TT-conjugated UEA-1 as a control for 
the effi   cacy of the NKM 16  –  2-4  –  based M cell  –  targeted mucosal 
vaccines. As expected, brisk TT-specifi  c serum IgG and muco-
sal IgA responses were induced in mice immunized with TT-
conjugated NKM 16  –  2-4, whereas TT-conjugated control rat 
  Figure 1.     Immunohistochemical analysis for the specifi  city of NKM 16  –  2-4. (A) Immunohistochemical analysis of PPs revealed that NKM 16  –  2-4 
specifi  cally reacted with UEA-1  –  positive M cells (red arrows), but not UEA-1  –  positive goblet cells (yellow arrowheads). (B) Electronmicroscopic analysis 
revealed that typical M cells, which had short and irregular microvilli and pocket structures containing lymphocytes and/or monocytes, specifi  cally reacted 
with NKM 16  –  2-4. Positive reactions are shown by gold particles (18 nm). IEC, intestinal epithelial cell. (C) Whole-mount staining of PPs and villous epi-
thelium demonstrated that, in addition to PP-associated M cells, UEA-1  –  positive villous M cells were specifi  cally recognized by NKM 16  –  2-4. Bars, 50    m.   2792 A NOVEL M CELL–SPECIFIC CARBOHYDRATE-TARGETED MUCOSAL VACCINE | Nochi et al.
be lower than those in a previous study (  20  ), this discrepancy 
might have been caused by diff  erences in the mouse haplo-
type or the sources of TT and CT. Despite the discrepancy, 
our current fi  ndings emphasize the eff  ectiveness of the newly 
established NKM 16  –  2-4 for the targeting of vaccine antigen 
to M cells to induce antigen-specifi  c immune responses. 
  Moreover, when mice were orally immunized with bot-
ulinum toxoid (BT) conjugated with NKM 16  –  2-4 or control 
rat IgG (in total, each 200     g contained 50     g BT per mouse) 
in the presence of CT, brisk botulinum toxin  –  specifi  c serum 
IgG and fecal IgA responses were induced in mice immu-
nized with BT-conjugated NKM 16  –  2-4, but not in those 
immunized with BT-conjugated control rat IgG (  Fig. 2 C  ). 
In addition, the mice immunized with BT-conjugated NKM 
16  –  2-4 survived after challenge with 200 ng (10,000  ×   LD  50  ) 
of botulinum toxin, whereas the mice immunized with BT-
conjugated control rat IgG died within 3 h (  Fig. 2 D  ). These 
data strongly indicate that the M cell-targeted mucosal vaccine 
with NKM 16  –  2-4 can eff  ectively induce protective immunity 
with the minimum dose of vaccine antigen. 
  To confi  rm the mechanism by which the NKM 16  –  2-4  –
  based M cell  –  targeted mucosal vaccine induces brisk anti-
gen-specifi  c immune responses in the systemic and mucosal 
compartments, and its universality, OVA was then chosen 
as a prototype antigen with low antigenicity. An immuno-
cytochemical analysis revealed that Alexa Fluor 647  –  labeled 
OVA conjugated with NKM 16  –  2-4 and FITC-conjugated 
avidin specifi  cally reacted with UEA-1  –  positive isolated M 
cells in vitro (  Fig. 3 A  ), and intestinal loop assay clearly 
demonstrated that it specifi  cally attached to the apical sur-
faces of M cells and was subsequently taken up into the cyto-
plasmic regions of M cells in vivo (  Fig. 3 B  ).   Furthermore, 
brisk increases in the levels of OVA-specifi   c serum IgG 
were induced in mice immunized with only 200     g OVA-
conjugated NKM 16  –  2-4 (containing 50     g OVA), but not 
with the same amount of OVA-conjugated control rat IgG 
(  Fig. 3 C  ). Our previous study showed that amounts of 
OVA as high as 1 mg were required to induce OVA-spe-
cifi  c immune responses (  5  ); now, oral immunization with 
even small amounts of poorly immunogenic antigens (e.g., 
OVA) is possible by using the M cell  –  targeting concept 
with NKM 16  –  2-4. 
  We could not directly compare the effi   cacy of NKM 
16  –  2-4  –  based mucosal vaccine with those of already pub-
    Table I.        Immunological and biochemical characteristics of 
newly established mAb (NKM 16-2-4) and UEA-1 in M cells 
mAb/lectin Specifi  city Cell specifi  city
M cells Epithelial 
cells
Goblet 
cells
NKM 16-2-4     (1,2) fucose-
containing 
  carbohydrate moiety 
+  −   − 
UEA-1     (1,2) fucose +  − +
  Figure 2.     Development of an M cell  –  targeted mucosal vaccine with 
NKM 16  –  2-4. (A) FITC-conjugated NKM 16  –  2-4, but not FITC-conjugated 
control rat IgG, was specifi  cally attached to the apical surfaces of M cells 
in FAE of PPs within 10 min of inoculation in an intestinal loop assay. The 
NKM 16  –  2-4 was subsequently taken up into the cytoplasmic regions of 
M cells within 30 min and reached the basal membrane of M cells within 4 h. 
Bars, 10     m. (B) TT conjugated with NKM 16  –  2-4 effectively induced high-
level, TT-specifi  c serum IgG and fecal IgA responses, unlike TT conjugated 
with control rat IgG or UEA-1. Furthermore, the levels were superior to those 
in mice immunized with 10 times the amount of noncoupled TT (500    g). 
*, P   <   0.01, Tukey  ’  s   t   test. (C) BT-conjugated NKM 16  –  2-4, but not BT-
conjugated control rat IgG, induced brisk botulinum toxin  –  specifi  c serum 
IgG and fecal IgA responses. (D) Mice orally immunized with BT-conjugated 
NKM 16  –  2-4 were protected from an i.p. challenge with 10,000  ×   LD  50   type  A 
botulinum toxin. Data are expressed as the mean   ±   the SD.     
lished     1-based mucosal vaccines (  10, 11  ) because the latter 
systems have been used for nasal, but not oral, vaccines and 
no information is currently available on whether     1 possesses JEM VOL. 204, November 26, 2007  2793
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  Identifi  cation of antigens recognized by NKM 16  –  2-4 
  In attempts to elucidate the antigen-sampling mechanism of 
M cells for the induction of antigen-specifi  c immune re-
sponses, a major drawback has been the lack of knowledge of 
the specifi  c genes and the corresponding molecules expressed 
by M cells. In addition, no information regarding which mu-
rine M cell  –  specifi  c glycoproteins are recognized by UEA-1 
is currently available, although UEA-1 is used extensively as 
a specifi  c marker of M cells in mice. Therefore, we tried to 
identify the membrane antigen recognized by NKM 16  –  2-4 
by using a proteomics approach with liquid chromatography  –
  tandem mass spectrometry (LC-MS/MS) after immuno-
precipitation of an M cell lysate with NKM 16  –  2-4. 4 major 
bands (3 bands   >  250 kD and 1 band of     150 kD) were pre-
cipitated by NKM 16  –  2-4 (  Fig. 4 A  ), and these were identi-
fi  ed by LC-MS/MS as maltase glucoamylase (top three bands) 
and alanyl (membrane) aminopeptidase (bottom band).   These 
two molecules, which have been reported as intestinal en-
zymes of 410, 275, and 260 kD (  21  ), and 150 kD, respec-
tively, (  22  ) under denatured conditions, are distributed at the 
brush borders of epithelial cells for the fi  nal digestion of di-
etary nutrients (  21, 22  ). Because they were not homologous 
specifi  city for villous M cells. However, our strategy for us-
ing NKM 16  –  2-4 as an M cell  –  targeting vehicle might be 
superior, because NKM 16  –  2-4 possesses specifi  city for both 
villous M cells and PP-associated M cells. In support of our 
hypothesis, our previous data showed that villous M cells 
are capable of taking up orally administered antigens for 
the induction of PP-independent, antigen-specifi  c immune 
responses (  4  ). However, it should be noted that TT- or 
OVA-specifi  c immune responses were not eff  ectively induced 
without the presence of the mucosal adjuvant CT, even if 
the antigen was targeted to M cells by using NKM 16  –  2-4. 
This fi  nding could be explained by the observation that the 
gastrointestinal immune system generally operates via a so-
phisticated mucosal regulatory network to avoid unnecessary 
hyperimmune responses to the numerous orally encoun-
tered antigens in the harsh environment of the intestinal tract 
(  3  ). Therefore, it is essential to use the mucosal adjuvant, 
which temporarily breaks the mucosal regulatory network 
system, to activate gastrointestinal immunity. In practical terms, 
further studies are needed to develop a safe mucosal adjuvant 
and take advantage of M cell  –  targeted mucosal vaccines with 
NKM 16  –  2-4. 
  Figure 3.     Effective uptake and universality of the M cell  –  targeted mucosal vaccine. (A) Immunocytochemical analysis showed that an M cell  –
  targeted OVA vaccine composed of Alexa Fluor 647  –  conjugated OVA, FITC-conjugated avidin, and NKM 16  –  2-4 specifi  cally reacted with isolated UEA-1  –
  positive M cells. (B) In an intestinal loop assay, the M cell-targeted OVA specifi  cally attached to the apical surfaces of M cells (red arrows) and was 
immediately taken up into the cytoplasmic regions of M cells. Bars, 10     m. (C) Orally administered OVA-conjugated NKM 16  –  2-4 effectively induced an 
OVA-specifi  c serum IgG response, whereas an OVA-conjugated control rat IgG did not. Data are expressed as the mean   ±   the SD.     2794 A NOVEL M CELL–SPECIFIC CARBOHYDRATE-TARGETED MUCOSAL VACCINE | Nochi et al.
  On the basis of our hypothesis, we transfected Chinese 
hamster ovary (CHO) cells with the genes encoding murine 
fucosyl transferase 1 (mFUT1) or mFUT2, which have been 
identifi  ed as     (1,2) fucose transfer enzymes (  23  ). A fl  ow cyto-
metric analysis revealed that both NKM 16  –  2-4 and UEA-1 
specifi  cally reacted with CHO cells expressing mFUT1 or 
mFUT2, but neither NKM 16  –  2-4 nor UEA-1 showed spec-
ifi  city for original or empty vector  –  transfected CHO cells (  Fig. 
4 C  ). In addition, a blocking analysis showed that pretreatment 
of NKM 16  –  2-4 with     -  l  -fucose did not completely abolish 
reactivity to mFUT1- or mFUT2-expressing transfectants, al-
though UEA-1 reactivity to these transfectants was dramatically 
decreased (Fig. S4, available at http://www.jem.org/cgi/
content/full/jem.20070607/DC1), indicating that the epitope 
recognized by NKM 16  –  2-4 is an mFUT1- or mFUT2-
mediated carbohydrate complex containing     (1,2) fucose that is 
diff  erent from the UEA-1  –  reactive portion of     (1,2) fucose. 
  Because immunohistochemical analysis demonstrated that 
UEA-1, but not NKM 16  –  2-4, recognized goblet cells in the 
intestinal villi (  Fig. 1 A  ), we turned to examining the diff  erences 
in recognition patterns between NKM 16  –  2-4 and UEA-1 
by using a mutant line of CHO cells to elucidate the impor-
tance of the glycosylation of M cells and goblet cells in the 
mucosal immune system. When the mFUT1 or mFUT2 gene 
was introduced into a mutant line of CHO cells (Lec2) with 
an inactivated CMP-sialic acid transporter (  24  ), the reactivity 
of NKM 16  –  2-4, but not of UEA-1, was higher in these 
transfectants than in the mFUT1- or mFUT2-expressing 
original CHO cells; however, mFUT1- or mFUT2-expressing 
Lec1 cells with inactivated GlcNAc transferase I (i.e., a lack 
of   N  -glycans) (  25  ) or Lec8 cells with inactivated UDP-galactose 
transporter (  26  ) were not recognized at all by NKM 16  –  2-4. 
On the other hand, we observed very low reactivity of  UEA-1 
to mFUT1- or mFUT2-expressing Lec8 cells, although 
mFUT1- or mFUT2-expressing Lec1 cells were not recog-
nized by UEA-1. This is because UEA-1 might recognize 
    (1,2) fucose, which is linked to very low levels of galactose on 
  N   glycans in mFUT1- or mFUT2-expressing Lec8 cells be-
cause it has been reported that Lec8 cells retain 10  –  20% of their 
galactosylation (  26  ), and no information is currently available 
on whether     (1,2) fucose links to anything other than galactose. 
These data suggest that sialic acid might be useful in distin-
guishing the reactivity of NKM 16  –  2-4, but not UEA-1 to 
galactose-binding     (1,2) fucose on   N  -glycans, although the re-
activity to     (1,2) fucose regulated by   O  -glycans remains unclear. 
Thus, our initial immunohistochemical analyses demonstrated 
that the specifi  city of NKM 16  –  2-4 to UEA-1  –  positive M cells, 
but not UEA-1  –  positive goblet cells, is attributable to the 
existence of abundant sialic acids neighboring the     (1,2) 
fucose  –  containing carbohydrate moiety on goblet cells, but not 
on M cells. With the exception of their expression patterns at 
the tissue level, there is currently little reliable information 
available on the glycobiological and molecular biological dif-
ferences between mFUT1 and mFUT2 as     (1,2) fucosyl-
transferases (  23  ). Therefore, further studies, especially in terms 
of in situ expression patterns at a cellular level at inductive 
with each other, and subsequent in situ hybridization analysis 
demonstrated that their mRNAs were ubiquitously and abun-
dantly expressed in the intestinal epithelium, including in M 
cells (Fig. S3, available at http://www.jem.org/cgi/content/
full/jem.20070607/DC1), we hypothesized that NKM 16 – 
2-4 possesses specifi  city for the M cell  –  specifi  c carbohydrate 
moiety containing     (1,2) fucose, as the precipitated antigens 
were commonly recognized by UEA-1 (  Fig. 4 B  ). 
  Figure 4.     Identifi  cation of the antigen recognized by NKM 16  –  2-4. 
(A) Immunoprecipitation and Western blot analysis with NKM 16  –  2-4 
were performed with an M cell lysate. 4 major bands (3 bands   >  250 kD 
and 1 band of     150 kD) were precipitated. A subsequent LC-MS/MS anal-
ysis identifi  ed the three top bands as maltase glucoamylase and the bot-
tom band as alanyl (membrane) aminopeptidase. (B) Lectin blot analysis 
performed after immunoprecipitation with NKM 16  –  2-4 showed that the 
precipitated antigens were all recognized by UEA-1. (C) mFUT1 and mFUT2 
genes were transfected into original CHO cells and CHO-derived mutant 
lines (Lec1, Lec2, and Lec8 cells) with a pIRES2-EGFP expression system, 
and the specifi  city of NKM 16  –  2-4 and UEA-1 for EGFP-expressing trans-
fectants was analyzed. NKM 16  –  2-4 and UEA-1 specifi  cally reacted with 
mFUT1- or mFUT2-expressing original CHO cells. The reactivity of NKM 
16  –  2-4 but not UEA-1 to mFUT1- or mFUT2-expressing Lec2 cells was 
enhanced compared with that to mFUT1- or mFUT2-expressing CHO cells. 
On the other hand, mFUT1- or mFUT2-expressing Lec1 or Lec8 cells were 
not recognized at all by NKM 16  –  2-4.     JEM VOL. 204, November 26, 2007  2795
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was incubated with the same volume of avidin (1 mg/ml; Sigma-Aldrich). 
The complexes were then incubated with twice the volume of biotinylated 
NKM 16  –  2-4, biotinylated control rat IgG (Sigma-Aldrich), or biotinylated 
UEA-1 (Vector Laboratories; each 1 mg/ml). Mice were orally immunized 
with the complexes (in total, each 200     g contained 50     g TT or BT per 
mouse), noncoupled TT (50 or 500     g per mouse), or PBS alone 3 times 
(once a week), together with 10     g CT (List Biological Laboratories) as a 
mucosal adjuvant. 7 d after the fi  nal immunization, serum and fecal extracts 
were collected and analyzed for TT- or type A botulinum toxin  –  specifi  c 
serum IgG and fecal IgA responses by ELISA, as previously described (  5, 27  ). 
To examine the protective immunity, the mice were challenged via the i.p. 
route with 200 ng type A botulinum toxin (10,000  ×   LD  50   i.p.) diluted in 
100     l of 0.2% gelatin/PBS (  27  ). To confi  rm the universality of M cell  – 
targeted mucosal vaccine with NKM 16  –  2-4, OVA (Sigma-Aldrich) was con-
jugated with NKM 16  –  2-4 or control rat IgG and orally immunized together 
with 10     g CT. In addition, intestinal loop assay was performed by using M 
cell  –  targeted OVA composed of Alexa Fluor 647-conjugated OVA (Invitro-
gen), FITC-conjugated avidin (Sigma-Aldrich), and NKM 16  –  2-4 or con-
trol rat IgG. Conjugation of NKM 16  –  2-4 or control rat IgG and the protein 
antigen was confi  rmed by sandwich ELISA (unpublished data). 
  Analysis of antigen recognized by NKM 16  –  2-4.     To identify the anti-
gen recognized by NKM 16  –  2-4, we performed an immunoprecipitation 
assay with NKM 16  –  2-4 followed by an LC-MS/MS analysis. In brief, a lysate 
of M cells was incubated with 10     g/ml NKM 16  –  2-4 or an isotype control 
antibody (rat IgG2c; BD Biosciences) followed by protein G  –  Sepharose (GE 
Healthcare). Immune complexes were analyzed by SDS-PAGE and Western 
or lectin blot with 5     g/ml biotinylated NKM 16  –  2-4, 5     g/ml biotinylated 
isotype control antibody (biotin-conjugated rat IgG2c; BD Biosciences), or 
5     g/ml biotinylated UEA-1 (Vector Laboratories) and ABC  –  AP complex 
(Vector Laboratories). To identify the precipitated antigen, LC-MS/MS analysis 
was performed after digestion with 50 nM trypsin gold (Promega). 
  Transfection of cells.     mFUT1 and mFUT2 genes were synthesized from 
mRNAs from intestinal tissue, including PPs, using specifi  c primers (mFUT1: 
sense, 5    -TACTAA  GCTAGC  ATGTGGACTCCCAGCCG  GAGGCAG-3    , 
anti  sense, 5    -GCTAGC  GGATCC  TCAGACCAATCTAAAAAGACTGTC-3    ; 
mFUT2: sense, 5    -ATCTAA  GCTAGC  ATGGCGAGTGCCCAGGTAC-
CTTTC-3    , antisense, 5    -TGCAGC  GAATTC  TTAGTGCTTAAGGAGT-
GGGGACAG-3    ; NheI and BamHI [mFUT1] and NheI and EcoRI [mFUT2] 
restriction enzyme sites are shown by underlining) by RT-PCR and inserted 
into pIRES2-EGFP vector (BD Biosciences). These plasmids were then trans-
formed into CHO-K1 cells (CCL-61; American Type Culture Collection) 
and three CHO-cell  –  derived mutant lines (Lec1, CRL-1735 [reference   25  ]; 
Lec2, CRL-1736 [reference   24  ]; and Lec8, CRL-1737 [reference   26  ]). 
2 d after transfection, the cells were stained with 500 ng/ml Alexa Fluor 647 – 
conjugated NKM 16  –  2-4 and 500 ng/ml PE-conjugated UEA-1, followed 
by the application of 10     l/test VIA-PROVE (BD Biosciences). They were 
then analyzed by fl  ow cytometry with FACSCalibur (Becton Dickinson). 
For blocking analysis, 500 ng/ml Alexa Fluor 647  –  conjugated NKM 16  –  2-4 
or 500 ng/ml PE-conjugated UEA-1 was fi  rst pretreated with 0.5 M     -L-
fucose (Wako). 
  Data analysis.     Data are expressed as the mean   ±   the SD. All analyses for 
statistically signifi  cant diff  erences were performed by Tukey  ’  s   t   test, with P   <   
0.01 considered signifi  cant (denoted in the fi  gures with an asterisk). 
  Online supplemental material.     Fig. S1 shows the specifi  city of NKM 
16  –  2-4 to isolated UEA-1  –  positive M cells. Fig. S2 shows that NKM 16  –  2-4 
specifi  cally reacts with M cells in NALT, similar to its reaction with PP-
associated M cells. Fig. S3 shows the expression of maltase glucoamylase 
and alanyl aminopeptidase mRNAs in PPs. Fig. S4 shows that NKM 16  –  2-4 
reacts with diff  erent form of UEA-1  –  reactive portion of     (1,2) fucose. 
The online version of this article is available at http://www.jem.org/cgi/
content/full/jem.20070607/DC1. 
sites, such as in PPs, are needed to elucidate the role of the 
carbohydrate moiety containing     (1,2) fucose in the mucosal 
immune system. 
  In summary, we established a novel M cell  –  specifi  c mAb 
(NKM 16  –  2-4; rat IgG2c) that selectively recognizes M cells, 
but not goblet cells or epithelial cells, and we characterized the 
M cell  –  specifi  c carbohydrate moiety containing     (1,2) fucose. 
Our strategy for M cell  –  targeted vaccination with NKM 16  – 
2-4 is attractive for the development of mucosal vaccines. 
    MATERIALS AND METHODS   
  Animals.     Female BALB/c mice, Crlj: CD1-  Foxn1  nu     mice, and SD rats 
between 6 and 8 wk old were obtained from CREA and Charles River Labo-
ratories. All of them were maintained in the experimental animal facility at 
the Institute of Medical Science, the University of Tokyo, and experiments 
were performed according to the guidelines provided by the Animal Care 
and Use Committee of the University of Tokyo. 
  Establishment of an M cell  –  specifi  c mAb.     The M cell  –  enriched fraction 
was prepared from murine PPs as previously described, with some modifi  ca-
tion, by using UEA-1 (  4  ). In brief, cells isolated from murine PPs were fi  xed 
in 4% paraformaldehyde (Wako) and stained with 500 ng/ml PE-conjugated 
UEA-1 (Biogenesis). UEA-1  –  positive cells were sorted by a FACSAria cell 
sorter (Becton Dickinson) and injected into the footpads of SD rats (10  6   cells/
rat) 4 times at 2-wk intervals, with TiterMax Gold (TiterMax) as an adjuvant. 
4 d after the fi  nal immunization, lymphocytes isolated from the spleen and 
inguinal lymph nodes of the immunized rats were fused with P3X63-
AG8.653 myeloma cells (CRL-1580; American Type Culture Collection) in 
the presence of 50% (wt/vol) polyethylene glycol 1500 (Roche). Established 
hybridomas were injected into Crlj: CD1  -    Foxn1  nu     mice, and mAbs were 
then purifi  ed from ascitic fl  uids by using protein G  –  Sepharose (GE Health-
care) and labeled with EZ-Link Sulfo-NHS-LC-biotin (Thermo Fisher Sci-
entifi  c), FITC (Sigma-Aldrich), or Alexa Fluor 647 (Invitrogen). 
  Immunohistochemical analysis.     One monoclonal antibody (NKM 16  – 
2-4; rat IgG2c) was selected on the basis of the initial screening and its speci-
fi  city to M cells determined by immunohistochemical and whole-mount 
staining analyses, as described previously, with some modifi  cation (  4  ). In 
brief, after a blocking step with 1% BSA, 7-    m fi  xed frozen sections or fi  xed 
tissues containing PPs were stained with 5     g/ml FITC-conjugated NKM 
16  –  2-4 or FITC-conjugated isotype control (FITC-conjugated rat IgG2c; 
MBL International) and 1     g/ml tetrarhodamine isothiocyanate  –  conjugated 
UEA-1 (Vector Laboratories). The sections were then counterstained with 
400 ng/ml DAPI (Sigma-Aldrich) for histochemical analysis and analyzed 
under a confocal laser-scanning microscope (TCS SP2; Leica). For electron-
microscopic analysis, ultrathin sections (100 nm) were incubated with 1     g/ml 
purifi  ed NKM 16  –  2-4 after blocking with 1% BSA, followed by 18-nm gold 
particle  –  conjugated goat anti  –  rat IgG (Jackson Immunoresearch Laboratories) 
diluted 1:10. Finally, the sections were stained with 4% uranyl acetate and 
analyzed under a transmission electron microscope (JEM100S; JEOL). 
  Uptake of NKM 16  –  2-4 by M cells.     After the mice were anesthetized 
with 2 mg ketamine (Sigma-Aldrich), we injected 100     g of FITC-conju-
gated NKM 16  –  2-4 or FITC-conjugated control rat IgG (Sigma-Aldrich) 
into intestinal loops containing PPs, in accordance with our previous study (  4  ). 
The mice were killed 10 or 30 min, or 4 h, after the inoculation, and frozen 
sections (7     m) of intestinal loop were prepared and analyzed under a con-
focal laser-scanning microscope after counterstaining with DAPI. 
  M cell  –  targeted vaccination.     TT (provided by the Research Foundation 
for Microbial Diseases, Osaka University, Osaka, Japan) and type A BT (pre-
pared according to a previous study; reference [  27  )]) were fi  rst treated with 
EZ-Link Sulfo-NHS-LC-biotin. Next, biotinylated TT or BT at 1 mg/ml 2796 A NOVEL M CELL–SPECIFIC CARBOHYDRATE-TARGETED MUCOSAL VACCINE | Nochi et al.
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